Could protein kinase inhibitors become a next generation pharmacotherapy for non-Hodgkin’s lymphoma?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Could protein kinase inhibitors become a next generation pharmacotherapy for non-Hodgkin’s lymphoma?

Published:2024-04-12 Issue:6 Volume:25 Page:637-640
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Cohen Melanie¹,Graf Solomon A.²³⁴

Affiliation:

1. Pharmacy Section, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA

2. Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA

3. Department of Hematology/Oncology, University of Washington School of Medicine, Seattle, WA, USA

4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2024.2354915

Reference21 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes

2. Morschhauser F, Zinzani PL, Kröger N, et al. Indolent lymphomas. EBMT/EHA CAR-T cell handbook. Cham: Springer; 2022. Chapter 15. 2022 Feb.

3. From genetics to the clinic: a translational perspective on follicular lymphoma

4. B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia.

5. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP